Portnoy Mark L. 4

4 · CRYO CELL INTERNATIONAL INC · Filed Jan 5, 2023

Form 4

Period: 2023-01-03

DirectorCo-CEO10% Owner

Transactions

Award
Stock Option
2023-01-03$4.77/sh+25,000$119,250→ 25,000 total
Exercise: $4.77From: 2023-01-03Exp: 2028-01-03→ Common Stock (25,000 underlying)

Holdings

Stock Option
Exercise: $7.28From: 2019-12-20Exp: 2029-12-20→ Common Stock (20,000 underlying)
20,000
Stock Option
Exercise: $12.27From: 2021-12-22Exp: 2028-12-22→ Common Stock (100,000 underlying)
100,000
Stock Option
Exercise: $7.92From: 2018-03-08Exp: 2023-03-08→ Common Stock (20,000 underlying)
20,000
Stock Option
Exercise: $13.50From: 2021-12-22Exp: 2024-12-22→ Common Stock (20,000 underlying)
20,000
Common Stock
(indirect: By 401(k))
42,266
Common Stock
(indirect: By Partnership)
71,529
Common Stock
821,973
Stock Option
Exercise: $7.53From: 2019-08-30Exp: 2029-08-30→ Common Stock (22,222 underlying)
22,222

Footnotes (5)

[F1]Shares of Common Stock held by Capital Asset Fund #1 Limited Partnership, as to which Mark L. Portnoy may be deemed the beneficial owner as its general partner.
[F2]The stock options are subject to the approval of the 2022 Equity Incentive Plan, which vote is expected to occur at the Company's 2022 Annual Meeting.
[F3]One-third of the stock options will vest on December 22, 2022, one-third will vest on December 22, 2023 and one-third on December 22, 2024.
[F4]Stock options vest immediately if the price of the Company's stock reaches $25.00 per share during the seven-year option term.
[F5]11,250 options vest upon issuance, 11,250 options vest on 1/2/2024 and 2,500 options vest on 1/2/2025.

Documents

1 file